Clinical Case Presentation: A 53-Year-Old Woman with Metastatic ER/PR+ HER2+ Breast Cancer and Brain Metastases

Video

Dr Stefania Maraka presents the case of a 53-year-old woman with de novo metastatic mutated ER/PR+ HER2+ breast cancer and brain metastases.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Related Content
Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Tim Cortese
January 10th 2025
Article

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Real-World Data Shows Improved Responses for Pembrolizumab/Chemo in TNBC

Real-World Data Shows Improved Responses for Pembrolizumab/Chemo in TNBC

Tim Cortese
January 3rd 2025
Article

A study of patients who received the KEYNOTE-522 regimen showed an improved pathologic complete response in real-world data vs what study data showed.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

LumiSystem in Lumpectomy May Reduce or Omit Radiation in Breast Cancer

LumiSystem in Lumpectomy May Reduce or Omit Radiation in Breast Cancer

Tim Cortese
December 30th 2024
Article

Broader margins used in lumpectomies can lead to a reduced radiation target area in patients with breast cancer, according to results from a study presented at the 2024 SABCS.

Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

ONCOLOGY Staff
December 29th 2024
Article

In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.